Helix BioPharma Corp. (TSX: HBP, OTC PINK: HBPCD, FRANKFURT: HBP0) presented new data on its CEACAM6-directed antibody-drug conjugate (ADC) program at the 16th Annual World ADC London conference, held in London, United Kingdom. The presentation, titled "Next-Generation ADCs: Unlocking the Potential of CEACAM6-Directed Targeted Therapies," was delivered by Jonathan Davis, PhD, Director of ADC Discovery at Helix BioPharma, as part of the conference's opening day.
Dr. Davis was selected to present as part of the conference's Seminar Day program, which brings together leading ADC experts to address key challenges and opportunities in next-generation conjugate design, safety, combination strategies, and regulatory development. His participation underscores Helix's growing leadership in the development of innovative ADC technologies. The World ADC London conference continues over the following two days with a comprehensive scientific program covering advances in ADC discovery, development, and clinical translation.
The presentation highlighted CEACAM6 as a highly attractive therapeutic target, based on its elevated expression across a broad range of epithelial cancers, its association with poor clinical outcomes, and its limited expression in healthy tissues. Dr. Davis also presented data supporting the tumor-selective binding profile of Helix's proprietary anti-CEACAM6 VHH, a single-domain antibody fragment derived from camelid antibodies (also known as a "nanobody"), which demonstrated preferential binding to tumor-expressed CEACAM6. This highly selective binding profile supports the development of next-generation ADCs designed to deliver potent therapeutic payloads directly to cancer cells while minimizing off-target effects, and builds on the clinical foundation set by Tumor Defense Breaker™, L-DOS47, Helix's lead CEACAM6-targeted candidate, which has demonstrated favorable safety and encouraging clinical activity in Phase I/II studies in non-small cell lung cancer (NSCLC).
“CEACAM6 represents a compelling and underexploited target with broad potential across multiple hard-to-treat cancers,” said Dr. Davis. “Our proprietary VHH-based targeting approach enables highly selective tumor binding, supporting the development of next-generation ADCs designed to maximize therapeutic impact while minimizing off-target effects. Our presentation generated strong interest and discussion among conference participants, reflecting the growing recognition of CEACAM6 as an important emerging target in oncology.”
A copy of Dr. Davis' presentation is available on the Company's website under the “Events and Presentations” page at: https://helixbiopharma.com/wp-content/uploads/2026/02/Unlocking-the-Potential-of-CEACAM6.pdf.
About World ADC London: World ADC London is a global, annual conference dedicated to the discovery, development, and commercialization of antibody-drug conjugates (ADCs). Now in its 16th year, it is the longest-standing and one of the leading global conferences dedicated to ADC research and development. The event brings together more than 700 industry stakeholders from over 240 companies, including biopharma organizations, clinicians, investors, and regulatory experts, as well as a global faculty of more than 120 speakers. Learn more at https://worldadc-europe.com/.
About Helix BioPharma: Helix BioPharma is an oncology company that innovates from strength to bring near-term solutions for today's hardest-to-treat cancers. The Company's pipeline is led by Tumor Defense Breaker™ L-DOS47, a clinical-stage antibody-enzyme conjugate designed to prime CEACAM6-expressing tumors for increased sensitivity to therapy and augment the effectiveness of today's front-running anti-cancer treatments. L-DOS47 has completed Phase Ib studies in non-small cell lung cancer (NSCLC) and shares its CEACAM6-targeting foundation with Helix's next-generation bi-specific antibody-drug conjugates (ADCs), currently in discovery. The Company also advances two pre-IND candidates: (i) LEUMUNA™, an oral immune checkpoint modulator aimed at achieving durable remission in post-transplant leukemia relapse, and (ii) GEMCEDA™, a first-in-class oral gemcitabine prodrug with bioavailability on a par with IV, designed to expand treatment options for advanced cancers. For more information, please visit: https://www.helixbiopharma.com/.
